Get to know our clinical trials

Study of ASTX030 (cedazuridine in combination with azacitidine) in MDS, CMML or AML

THE PURPOSE OF THIS STUDY IS TO ANALYZE THE LEVELS OF THE EXPERIMENTAL DRUG ASTX030 IN THEIR BLOOD, TO ASSESS THE SAFETY AND TOLERABILITY OF THE DRUGS, AND TO FIND OUT HOW THE PARTICIPANTS RESPOND TO THE DRUG.

Imagen de la Dra. Ana Alfonso Piérola, especialista en Hematología de la Clínica Universidad de Navarra. La Dra. Alfonso se dedica al estudio y tratamiento de los síndromes mielodisplásicos y las leucemias mieloblásticas agudas.
Dr. Ana Alfonso Piérola [SP] Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • MULTI-PHASE, STEPWISE DOSE ESCALATION FOLLOWED BY AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY OF ORAL ASTX030 (COMBINED WITH CEDAZURIDINE AND AZACITIDINE) VS. SUBCUTANEOUS AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) OR ACUTE MYELOID LEUKEMIA (AML).
  • Code EudraCT: 2024-515098-93
  • Protocol number: ASTX030-01
  • Promoter: Taiho Oncology, Inc.
  • Molecule/Drug: ASTX030
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION